Treatment for chronic idiopathic constipation: Use and satisfaction from a nationwide survey of US participants.
abdominal pain
constipation
functional GI diseases
small intestine
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
18 Aug 2024
18 Aug 2024
Historique:
revised:
20
06
2024
received:
08
01
2024
accepted:
25
07
2024
medline:
19
8
2024
pubmed:
19
8
2024
entrez:
19
8
2024
Statut:
aheadofprint
Résumé
Chronic idiopathic constipation (CIC) is a disorder of gut-brain interaction characterized by a variety of bowel movement-related and abdominal symptoms. A greater understanding of medication use and satisfaction with symptom control may provide insights to optimize patient care. Therefore, we explored these aspects of the disorder in adults with CIC. This study assessed data collected from a large nationwide survey of adult participants in the United States, querying demographics, clinical characteristics, and comorbid conditions, as well as medication use, care-seeking behaviors, and satisfaction with symptom control. Participants were grouped into the CIC cohort if they met Rome IV criteria, with controls matched 1:1 according to age, sex, race, region, and Charlson Comorbidity Index score. All data were self-reported. Two thousand five hundred and thirty-three participants with CIC were matched 1:1 to controls. In the CIC cohort, abdominal pain was the most reported symptom leading to medication use: 15.9% of respondents were receiving a prescription medication in addition to an over-the-counter medication, while 26.3% were taking neither. In addition, only one-third were satisfied with the control of their symptoms; however, satisfaction was significantly higher in respondents taking a prescription medication (p < 0.001). The proportion of reported comorbidities was significantly higher in the CIC cohort versus the control cohort, with chronic pain, anxiety, and depression among the highest (p < 0.001 for all). This study emphasizes the need for better communication regarding prescription medications and their benefits, with the goal of further improving CIC patients' overall symptoms.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic idiopathic constipation (CIC) is a disorder of gut-brain interaction characterized by a variety of bowel movement-related and abdominal symptoms. A greater understanding of medication use and satisfaction with symptom control may provide insights to optimize patient care. Therefore, we explored these aspects of the disorder in adults with CIC.
METHODS
METHODS
This study assessed data collected from a large nationwide survey of adult participants in the United States, querying demographics, clinical characteristics, and comorbid conditions, as well as medication use, care-seeking behaviors, and satisfaction with symptom control. Participants were grouped into the CIC cohort if they met Rome IV criteria, with controls matched 1:1 according to age, sex, race, region, and Charlson Comorbidity Index score. All data were self-reported.
KEY RESULTS
RESULTS
Two thousand five hundred and thirty-three participants with CIC were matched 1:1 to controls. In the CIC cohort, abdominal pain was the most reported symptom leading to medication use: 15.9% of respondents were receiving a prescription medication in addition to an over-the-counter medication, while 26.3% were taking neither. In addition, only one-third were satisfied with the control of their symptoms; however, satisfaction was significantly higher in respondents taking a prescription medication (p < 0.001). The proportion of reported comorbidities was significantly higher in the CIC cohort versus the control cohort, with chronic pain, anxiety, and depression among the highest (p < 0.001 for all).
CONCLUSIONS AND INFERENCES
CONCLUSIONS
This study emphasizes the need for better communication regarding prescription medications and their benefits, with the goal of further improving CIC patients' overall symptoms.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14885Subventions
Organisme : AbbVie Inc.
Organisme : Ironwood Pharmaceuticals, Inc.
Informations de copyright
© 2024 The Author(s). Neurogastroenterology & Motility published by John Wiley & Sons Ltd.
Références
Wald A. Constipation: advances in diagnosis and treatment. JAMA. 2016;315(2):185‐191.
Simren M, Palsson OS, Whitehead WE. Update on Rome IV criteria for colorectal disorders: implications for clinical practice. Curr Gastroenterol Rep. 2017;19(4):15.
Lacy BE. Update on the management of chronic idiopathic constipation. Am J Manag Care. 2019;25 (Suppl)(4):S55‐S62.
Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393‐1407.e1395.
Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study. Gastroenterology. 2021;160(1):99‐114.e113.
Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta‐analysis. Am J Gastroenterol. 2011;106(9):1582‐1591.
Dimidi E, Cox C, Grant R, Scott SM, Whelan K. Perceptions of constipation among the general public and people with constipation differ strikingly from those of general and specialist doctors and the Rome IV criteria. Am J Gastroenterol. 2019;114(7):1116‐1129.
Scott SM, Simrén M, Farmer AD, et al. Chronic constipation in adults: contemporary perspectives and clinical challenges. 1: epidemiology, diagnosis, clinical associations, pathophysiology and investigation. Neurogastroenterol Motil. 2021;33(6):e14050.
Taylor DCA, Abel JL, Martin C, et al. Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient‐reported data: the chronic constipation and IBS‐C treatment and outcomes real‐world research platform (CONTOR). J Med Econ. 2020;23(10):1072‐1083.
Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25(5):599‐608.
Wald A, Scarpignato C, Kamm MA, et al. The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther. 2007;26(2):227‐236.
McCormick D. Managing costs and care for chronic idiopathic constipation. Am J Manag Care. 2019;25(4 Suppl):S63‐S69.
Rao SSC, Brenner DM. Efficacy and safety of over‐the‐counter therapies for chronic constipation: an updated systematic review. Am J Gastroenterol. 2021;116(6):1156‐1181.
Sonu I, Triadafilopoulos G, Gardner JD. Persistent constipation and abdominal adverse events with newer treatments for constipation. BMJ Open Gastroenterol. 2016;3(1):e000094.
Corsetti M, Brown S, Chiarioni G, et al. Chronic constipation in adults: contemporary perspectives and clinical challenges. 2: conservative, behavioural, medical and surgical treatment. Neurogastroenterol Motil. 2021;33(7):e14070.
Guerin A, Carson RT, Lewis B, Yin D, Kaminsky M, Wu E. The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population. J Med Econ. 2014;17(8):577‐586.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373‐383.
Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD‐7. Arch Intern Med. 2006;166(10):1092‐1097.
Kroenke K, Spitzer RL, Williams JB. The PHQ‐9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606‐613.
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4(5):353‐365.
Oh SJ, Fuller G, Patel D, et al. Chronic constipation in the United States: results from a population‐based survey assessing healthcare seeking and use of pharmacotherapy. Am J Gastroenterol. 2020;115(6):895‐905.
Basilisco G. Patient dissatisfaction with medical therapy for chronic constipation or irritable bowel syndrome with constipation: analysis of N‐of‐1 prospective trials in 81 patients. Aliment Pharmacol Ther. 2020;51(6):629‐636.
Heidelbaugh JJ, Stelwagon M, Miller SA, Shea EP, Chey WD. The spectrum of constipation‐predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden. Am J Gastroenterol. 2015;110(4):580‐587.
Sommers T, Corban C, Sengupta N, et al. Emergency department burden of constipation in the United States from 2006 to 2011. Am J Gastroenterol. 2015;110(4):572‐579.
Paré P, Gray J, Lam S, et al. Health‐related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from logic (longitudinal outcomes study of gastrointestinal symptoms in Canada), a naturalistic study. Clin Ther. 2006;28(10):1726‐1735.
Cai Q, Buono JL, Spalding WM, et al. Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population. J Med Econ. 2014;17(2):148‐158.